
Thomas M Jenkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7344713/publications.pdf Version: 2024-02-01



THOMAS M IENKINS

#	Article	IF	CITATIONS
1	Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. Journal of Neurology, 2009, 256, 305-319.	3.6	94
2	Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Annals of Neurology, 2010, 67, 99-113.	5.3	75
3	Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 510-518.	1.9	69
4	Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. Brain, 2016, 139, 816-828.	7.6	67
5	Contiguousâ€slice zonally oblique multislice (COâ€ZOOM) diffusion tensor imaging: Examples of in vivo spinal cord and optic nerve applications. Journal of Magnetic Resonance Imaging, 2009, 29, 454-460.	3.4	48
6	Optic neuritis: the eye as a window to the brain. Current Opinion in Neurology, 2017, 30, 61-66.	3.6	47
7	The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2014, 27, 524-531.	3.6	41
8	lmaging muscle as a potential biomarker of denervation in motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 248-255.	1.9	41
9	Dissecting structure–function interactions in acute optic neuritis to investigate neuroplasticity. Human Brain Mapping, 2010, 31, 276-286.	3.6	34
10	Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis Journal, 2010, 16, 555-565.	3.0	33
11	Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Communications, 2022, 4, fcac029.	3.3	29
12	Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain, 2020, 143, 3603-3618.	7.6	24
13	Clinical and Molecular Aspects of Motor Neuron Disease. Colloquium Series on Genomic and Molecular Medicine, 2013, 2, 1-60.	0.2	18
14	Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open, 2020, 10, e038911.	1.9	18
15	Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. Journal of the Neurological Sciences, 2018, 388, 79-83.	0.6	16
16	Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease. Journal of Neurology, 2020, 267, 244-256.	3.6	15
17	A prospective pilot study measuring muscle volumetric change in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 414-423.	1.7	14
18	A plea for equitable global access to COVIDâ€19 diagnostics, vaccination and therapy: The NeuroCOVIDâ€19 Task Force of the European Academy of Neurology. European Journal of Neurology, 2021, 28, 3849-3855.	3.3	14

THOMAS M JENKINS

#	Article	IF	CITATIONS
19	Simultaneous ALS and SCA2 associated with an intermediate-length <i>ATXN2</i> CAG-repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 579-582.	1.7	13
20	Primary prevention of COVIDâ€19: Advocacy for vaccination from a neurological perspective. European Journal of Neurology, 2021, 28, 3226-3229.	3.3	13
21	COVIDâ€19 vaccination hesitancy among people with chronic neurological disorders: A position paper. European Journal of Neurology, 2022, 29, 2163-2172.	3.3	13
22	Muscle MRI in motor neuron diseases: a systematic review. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 161-175.	1.7	12
23	Translational approaches to restoring mitochondrial function in Parkinson's disease. FEBS Letters, 2018, 592, 776-792.	2.8	10
24	VoxelHop: Successive Subspace Learning for ALS Disease Classification Using Structural MRI. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 1128-1139.	6.3	10
25	A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 905-913.	1.9	8
26	New developments in the treatment of optic neuritis. Eye and Brain, 2010, 2, 83.	2.5	6
27	Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis Journal, 2014, 20, 1299-1301.	3.0	6
28	The role of cranial and thoracic electromyography within diagnostic criteria for amyotrophic lateral sclerosis. Muscle and Nerve, 2016, 54, 378-385.	2.2	6
29	Reinnervation as measured by the motor unit size index is associated with preservation of muscle strength in amyotrophic lateral sclerosis, but not all muscles reinnervate. Muscle and Nerve, 2022, 65, 203-210.	2.2	6
30	Visual Acuity, Eye Movements and Visual Fields. , 2014, , 75-88.		5
31	Cognitive deficits in vasculitis of the nervous system: a cross-sectional study. Postgraduate Medicine, 2019, 131, 546-549.	2.0	2
32	Assessment of the Precision in Measuring Glutathione at <scp>3 T</scp> With a <scp>MEGAâ€PRESS</scp> Sequence in Primary Motor Cortex and Occipital Cortex. Journal of Magnetic Resonance Imaging, 2022, 55, 435-442.	3.4	2
33	Diagnosing and managing multiple sclerosis. Practitioner, 2009, 253, 25-30, 2-3.	0.3	2
34	A Dysphasic Diabetic with Confusion and Fever. Practical Neurology, 2005, 5, 230-235.	1.1	0
35	A wolf in sheep's clothing. Practical Neurology, 2016, 16, 153-156.	1.1	0
36	PO215â€Outcomes of neurology admissions to critical care. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A68.3-A68.	1.9	0

#	Article	IF	CITATIONS
37	Neurological letter from Bangladesh. Practical Neurology, 2020, 20, 435.2-445.	1.1	0
38	GPs have pivotal role in managing MS. Practitioner, 2007, 251, 37-40, 42-3, 46 passim.	0.3	0